tirzepatide psychosis Psychiatric Safety of in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT - Wadden - 2026 - Obesity FDA Approves Tirzepatide, A Potential

Confirmatory GC-MS testing will not produce a positive result for semaglutide because it is not a controlled substance the panel is designed to find

A compounded preparation has not undergone that same FDA premarket review

About SURMOUNT-5 SURMOUNT-5 was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with injectable Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes

Draw the Dose: Use a new syringe for each injection